Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

por Heijnsdijk, E A M, der Kinderen, A, Wever, E M, Draisma, G, Roobol, M J, de Koning, H J
Publicado 2009

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands

por Gupta, A, Roobol, M J, Savage, C J, Peltola, M, Pettersson, K, Scardino, P T, Vickers, A J, Schröder, F H, Lilja, H
Publicado 2010

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors

por Wever, E M, Heijnsdijk, E A M, Draisma, G, Bangma, C H, Roobol, M J, Schröder, F H, de Koning, H J
Publicado 2013

What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study

por Luiting, H. B., Remmers, S., Valdagni, R., Boevé, E. R., Staerman, F., Rueb, J., Somford, D. M., Pickles, T., Rannikko, A., Roobol, M. J.
Publicado 2021

Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment

por de Bekker-Grob, E W, Bliemer, M C J, Donkers, B, Essink-Bot, M-L, Korfage, I J, Roobol, M J, Bangma, C H, Steyerberg, E W
Publicado 2013